Product Information
TAZAROTENE 0.1% GEL is a generic product labeled by Solaris Pharma Corporation, priced at $6.5039 per GM under NDC 73473031030. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Mar 20, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/g
Manufacturer
Solaris Pharma CorporationNDC
73473031030
Classification
Generic
Dosage Form
GEL
Route
CUTANEOUS
Effective Date
9/23/2026
Active Ingredients
TAZAROTENEApproval Type
Generic (ANDA)
FDA Application
ANDA213644FDA Approved
3/20/2023
TE Code
AB
On Market Since
1/3/2025
Pharmacological Classes
Price Statistics
The NADAC for TAZAROTENE 0.1% GEL has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 30.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.5039 per GM |
|---|---|
| All-time high | $9.4818 (Jun 12, 2024) |
| All-time low | $6.5039 (Sep 23, 2026) |
| 52-week high | $8.4457 |
| 52-week low | $6.5039 |
| Median price | $8.3030 |
| Average price | $8.1557 |
| Largest weekly change | -9.7% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Tazarotene market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solaris Pharma Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tazarotene market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAZAROTENE 0.1% GEL?
The current National Average Drug Acquisition Cost (NADAC) for TAZAROTENE 0.1% GEL, manufactured by Solaris Pharma Corporation, is $6.5039 per GM (NDC 73473031030), effective Sep 30, 2026.
How has the price of TAZAROTENE 0.1% GEL changed over time?
Over the history we have for it, the NADAC for TAZAROTENE 0.1% GEL has declined 30.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for TAZAROTENE 0.1% GEL?
Since Apr 17, 2024, the NADAC for TAZAROTENE 0.1% GEL has ranged from a low of $6.5039 (Sep 23, 2026) to a high of $9.4818 (Jun 12, 2024), with a median of $8.3030 per GM.
Are there cheaper alternatives to TAZAROTENE 0.1% GEL?
No other NADAC-published product currently shares the active ingredient and strength of TAZAROTENE 0.1% GEL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TAZAROTENE 0.1% GEL?
TAZAROTENE 0.1% GEL (NDC 73473031030) is labeled by Solaris Pharma Corporation, and CMS classifies it as a generic product.